Rosacea – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Rosacea – Pipeline Review, H1 2018’, provides an overview of the Rosacea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rosacea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Rosacea

– The report reviews pipeline therapeutics for Rosacea by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Rosacea therapeutics and enlists all their major and minor projects

– The report assesses Rosacea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Rosacea

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Rosacea

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Almirall SA

Amorepacific Corp

BioPharmX Inc

Cutanea Life Sciences Inc

ELORAC Inc

Foamix Pharmaceuticals Ltd

Hovione FarmaCiencia SA

Promius Pharma LLC

Sol-Gel Technologies Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rosacea Overview

Rosacea Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Rosacea Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rosacea Companies Involved in Therapeutics Development

Almirall SA

Amorepacific Corp

BioPharmX Inc

Cutanea Life Sciences Inc

ELORAC Inc

Foamix Pharmaceuticals Ltd

Hovione FarmaCiencia SA

Promius Pharma LLC

Sol-Gel Technologies Ltd

Rosacea Drug Profiles

AC-701 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACUD-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADP-13612 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benzoyl peroxide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologics for Dermatology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPX-04 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carbamide peroxide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-210 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-220 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-0003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FMX-103 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itraconazole Drug Profile

Product Description

Mechanism Of Action

R&D Progress

minocycline Drug Profile

Product Description

Mechanism Of Action

R&D Progress

minocycline hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-03 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omiganan pentahydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-14028 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rosacea Dormant Projects

Rosacea Discontinued Products

Rosacea Product Development Milestones

Featured News & Press Releases

Feb 15, 2018: Sol-Gel presents Phase 2 Data on VERED at the 2018 American Academy of Dermatology Annual Meeting

Dec 13, 2017: Hovione Announces Enrollment of First Patient in MARS, a Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel

Jun 12, 2017: Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam

1.5%

Jan 18, 2017: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study

Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients

Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea

Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea

May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea

May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study

May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea

Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea

Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK

Feb 26, 2014: Mirvaso the first and only treatment targeting the facial redness of rosacea approved by the European commission

Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea

Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Table 1: Number of Products under Development for Rosacea, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Products under Development by Companies, H1 2018

Table 4: Number of Products by Stage and Target, H1 2018

Table 5: Number of Products by Stage and Mechanism of Action, H1 2018

Table 6: Number of Products by Stage and Route of Administration, H1 2018

Table 7: Number of Products by Stage and Molecule Type, H1 2018

Table 8: Rosacea Pipeline by Almirall SA, H1 2018

Table 9: Rosacea Pipeline by Amorepacific Corp, H1 2018

Table 10: Rosacea Pipeline by BioPharmX Inc, H1 2018

Table 11: Rosacea Pipeline by Cutanea Life Sciences Inc, H1 2018

Table 12: Rosacea Pipeline by ELORAC Inc, H1 2018

Table 13: Rosacea Pipeline by Foamix Pharmaceuticals Ltd, H1 2018

Table 14: Rosacea Pipeline by Hovione FarmaCiencia SA, H1 2018

Table 15: Rosacea Pipeline by Promius Pharma LLC, H1 2018

Table 16: Rosacea Pipeline by Sol-Gel Technologies Ltd, H1 2018

Table 17: Rosacea Dormant Projects, H1 2018

Table 18: Rosacea Dormant Projects, H1 2018 (Contd..1), H1 2018

Table 19: Rosacea Discontinued Products, H1 2018

List of Figures

List of Figures

Figure 1: Number of Products under Development for Rosacea, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products by Top 10 Targets, H1 2018

Figure 4: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 5: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Routes of Administration, H1 2018

Figure 8: Number of Products by Stage and Routes of Administration, H1 2018

Figure 9: Number of Products by Molecule Types, H1 2018

Figure 10: Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports